Jayanthi Savio1, Nikhilesh Ravikumar Menon2, Arun Ramachandran Sudharma3, Vinutha Jairaj2, Joshila Mathew4. 1. Associate Professor, Department Microbiology, St John's Medical College , Bangalore, Karnataka, India . 2. PG Resident, Department Microbiology, St John's Medical College , Bangalore, Karnataka, India . 3. Junior Research Fellow, Department Microbiology, St. Johns Research Institute , Bangalore, Karnataka, India . 4. Senior Laboratory Technician, St John's Medical College , Bangalore, Karnataka, India .
Abstract
INTRODUCTION: Invasive Pulmonary Aspergillosis (IPA) is an important opportunistic infection with a high degree of mortality and morbidity. Galactomannan assay (GM assay) is found to be useful for diagnosis of IPA in patients with neutropenia. However the utility of this assay has not been evaluated in a mixed patient population with other co-morbid conditions. Though a kit cut-off of 0.5 has been recommended for the diagnosis of IPA, studies have reported a higher sensitivity with cut-offs more than 0.5. AIM: To establish an in-house cut-off and compare its utility with the kit cut-off to diagnose and categorize IPA as proven, probable and possible in patients with varied underlying risk factors. MATERIALS AND METHODS: This observational study was done in St John's Medical College, Bangalore, Karnataka, India from January 2013-December 2014. GM assay was performed on 25 each of healthy controls and clinically diagnosed cases of IPA. The in-house cut-off was calculated by plotting the Receiver Operating Characteristic Curve (ROC). RESULTS: The in-house cut-off was calculated to be 0.52. Using this and the kit cut-off (0.5), the Sensitivity, Specificity, Positive Predictive Value (PPV) and the Negative Predictive Value (NPV) were found to be 75%, 79%, 76%, 82% and 79%, 71%, 77%, 82% respectively. Diabetes mellitus was found to be associated with more than 50% of the patients. CONCLUSION: The established in house cut-off using healthy controls and patients with clinical diagnosis of IPA was not significantly different from that of the kit cut-off. Using either of these cut-offs, we could re-categorize two of the possible IPA cases in the probable group. This study helped to understand the clinical utility of this assay even in a mixed patient population with multiple co-morbidities.
INTRODUCTION:Invasive Pulmonary Aspergillosis (IPA) is an important opportunistic infection with a high degree of mortality and morbidity. Galactomannan assay (GM assay) is found to be useful for diagnosis of IPA in patients with neutropenia. However the utility of this assay has not been evaluated in a mixed patient population with other co-morbid conditions. Though a kit cut-off of 0.5 has been recommended for the diagnosis of IPA, studies have reported a higher sensitivity with cut-offs more than 0.5. AIM: To establish an in-house cut-off and compare its utility with the kit cut-off to diagnose and categorize IPA as proven, probable and possible in patients with varied underlying risk factors. MATERIALS AND METHODS: This observational study was done in St John's Medical College, Bangalore, Karnataka, India from January 2013-December 2014. GM assay was performed on 25 each of healthy controls and clinically diagnosed cases of IPA. The in-house cut-off was calculated by plotting the Receiver Operating Characteristic Curve (ROC). RESULTS: The in-house cut-off was calculated to be 0.52. Using this and the kit cut-off (0.5), the Sensitivity, Specificity, Positive Predictive Value (PPV) and the Negative Predictive Value (NPV) were found to be 75%, 79%, 76%, 82% and 79%, 71%, 77%, 82% respectively. Diabetes mellitus was found to be associated with more than 50% of the patients. CONCLUSION: The established in house cut-off using healthy controls and patients with clinical diagnosis of IPA was not significantly different from that of the kit cut-off. Using either of these cut-offs, we could re-categorize two of the possible IPA cases in the probable group. This study helped to understand the clinical utility of this assay even in a mixed patient population with multiple co-morbidities.
Entities:
Keywords:
Aspergillus; Fungal infection; Serological test
Authors: Chadi A Hage; John M Reynolds; Michelle Durkin; L Joseph Wheat; Kenneth S Knox Journal: J Clin Microbiol Date: 2006-12-13 Impact factor: 5.948
Authors: Reginald E Greene; Haran T Schlamm; Jörg-W Oestmann; Paul Stark; Christine Durand; Olivier Lortholary; John R Wingard; Raoul Herbrecht; Patricia Ribaud; Thomas F Patterson; Peter F Troke; David W Denning; John E Bennett; Ben E de Pauw; Robert H Rubin Journal: Clin Infect Dis Date: 2006-12-29 Impact factor: 9.079
Authors: Monique A S H Mennink-Kersten; Dorien Ruegebrink; Rocus R Klont; Adilia Warris; Françoise Gavini; Huub J M Op den Camp; Paul E Verweij Journal: J Clin Microbiol Date: 2005-08 Impact factor: 5.948
Authors: M Mikulska; E Furfaro; V Del Bono; A M Raiola; S Ratto; A Bacigalupo; C Viscoli Journal: J Antimicrob Chemother Date: 2012-04-11 Impact factor: 5.790
Authors: Ben De Pauw; Thomas J Walsh; J Peter Donnelly; David A Stevens; John E Edwards; Thierry Calandra; Peter G Pappas; Johan Maertens; Olivier Lortholary; Carol A Kauffman; David W Denning; Thomas F Patterson; Georg Maschmeyer; Jacques Bille; William E Dismukes; Raoul Herbrecht; William W Hope; Christopher C Kibbler; Bart Jan Kullberg; Kieren A Marr; Patricia Muñoz; Frank C Odds; John R Perfect; Angela Restrepo; Markus Ruhnke; Brahm H Segal; Jack D Sobel; Tania C Sorrell; Claudio Viscoli; John R Wingard; Theoklis Zaoutis; John E Bennett Journal: Clin Infect Dis Date: 2008-06-15 Impact factor: 9.079
Authors: Mojtaba Taghizadeh-Armaki; Mohammad T Hedayati; Vahid Moqarabzadeh; Saham Ansari; Saeed Mahdavi Omran; Hossein Zarrinfar; Sasan Saber; Paul E Verweij; David W Denning; Seyedmojtaba Seyedmousavi Journal: J Med Microbiol Date: 2017-07-12 Impact factor: 2.472